Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.890
+0.050 (1.76%)
At close: May 8, 2025, 4:00 PM
2.330
-0.560 (-19.38%)
Pre-market: May 9, 2025, 8:50 AM EDT
Protalix BioTherapeutics Revenue
In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%. Protalix BioTherapeutics had revenue of $18.22M in the quarter ending December 31, 2024, with 73.74% growth.
Revenue (ttm)
$53.40M
Revenue Growth
-18.47%
P/S Ratio
3.93
Revenue / Employee
$250,700
Employees
213
Market Cap
225.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 53.40M | -12.10M | -18.47% |
Dec 31, 2023 | 65.49M | 17.86M | 37.48% |
Dec 31, 2022 | 47.64M | 9.29M | 24.22% |
Dec 31, 2021 | 38.35M | -24.55M | -39.03% |
Dec 31, 2020 | 62.90M | 8.21M | 15.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PLX News
- 2 hours ago - Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results - PRNewsWire
- 4 days ago - Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 - PRNewsWire
- 4 weeks ago - Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline - Seeking Alpha
- 6 weeks ago - Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - PRNewsWire
- 7 weeks ago - Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond - Benzinga
- 7 weeks ago - Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - PRNewsWire
- 2 months ago - Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - PRNewsWire